RxDoctor Payments Data

Mayar Jundi, MD

Cardiovascular Disease · Saginaw, MINPI 1962601435

Payments from drug & device makers

$98,476in general payments, 2019–2025

Across 336 payments — averaging $293.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$45K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$23K
  • Astrazeneca UK Limited$12K
  • Merck$7K
  • Abbott$3K
  • Boehringer Ingelheim$2K
  • plus $6K from 38 others

What the payments were for

  • Travel & lodging$1,13914%
  • Food & beverage$6,72684%
  • Education$1091%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$98,476 in reported general payments places this provider in the 90th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$96,078
Medicare patients
551
Services billed
1,464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan448$605,243
JardianceEmpagliflozin299$374,572
EliquisApixaban346$356,160
FarxigaDapagliflozin Propanediol184$203,102
XareltoRivaroxaban59$72,584
Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine41$25,963
Repatha SureclickEvolocumab30$25,659
BrilintaTicagrelor20$22,443
CorlanorIvabradine Hcl24$19,511
Repatha SyringeEvolocumab17$14,862
Praluent PenAlirocumab14$10,119
Metoprolol Succinate420$9,508
Spironolactone432$4,642
Carvedilol255$4,149
Isosorbide Mononitrate ErIsosorbide Mononitrate118$3,489

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$763$605,243448 claims
Boehringer IngelheimJardiance$2,202$374,572299 claims
PfizerEliquis$397$356,160346 claims
AstraZenecaFarxiga, Brilinta$44,550$225,546204 claims
Johnson & JohnsonXarelto$261$72,58459 claims
AmgenCorlanor$269$19,51124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Saginaw

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →